PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Ren X, Cui H, Dai L, Chang L, Liu D, Yan W, Zhao X, Kang H, Ma X. J Cancer Res Clin Oncol. 2024 Mar 11; 150(3):119. Epub 2024 Mar 11.